The following is taken from OncoSec's website. Only certain portions are included here. For a complete description of OncoSec, please visit http://www.oncosec.com/ Do not base your trading decisions solely on the information presented here. Do your own DD. We are not licensed financial advisers. Nothing presented here should be construed
as buy/sell recommendations.
DISCUSSING OTHER STOCKS, SPAMMING, AND/OR PERSONAL ATTACKS WILL NOT BE TOLERATED!!
Who We Are
Cancer is a debilitating and swift-moving disease. To reach those affected by it, we need to move just as swiftly, with innovative treatments that extend lives and respect the need for quality of life.
Our mission at OncoSec is to pioneer and refine new electroporation technologies that save lives and enhance quality of life for those whose
skin cancers cannot be treated effectively with conventional treatment approaches.
Built on the foundation of a fast-paced, challenging, and entrepreneurial environment, OncoSec is committed to bringing proven treatments to the market quickly so those suffering today can have hope
for tomorrow. We will accomplish our mission through our entrepreneurial, results-driven culture, our proprietary technologies, our superior manufacturing and operational excellence, and strong
commercial leadership that identifies and expands the markets for our products.
At every step, we will fulfill our responsibilities to our stakeholders: the patients, physicians, healthcare workers, shareholders and employees who depend on-and are an integral part of-OncoSec's
General information about OncoSec Medical, Incorporated: http://www.otcmarkets.com/stock/ONCS/company-info
SEC filings for OncoSec Medical, Incorporated: http://www.otcmarkets.com/stock/ONCS/filings
OncoSec Medical: https://twitter.com/Oncosec
Punit Dhillon, CEO: https://twitter.com/PunitDhillon
Excellent video which includes an interview with a melanoma survivor and OncoSec's CEO Punit Dhillon: http://globalnews.ca/video/539117/melanoma-monday
Oncosec Spring 2014 Corporate Address: http://oncosec.com/oncosec-corporate-address-video-spring-2014/
An informative and comprehensive description of what OncoSec does: http://content.stockpr.com/oncosec/media/3edbc526ab7184e1257fcbcac727954e.pdf
A Selection of Significant Press Releases (PRs)
All news items about OncoSec Medical, Inc., can be found here: http://www.otcmarkets.com/stock/ONCS/news and here: http://ir.oncosec.com/company-news
OncoSec Announces First Patient Enrolled in Phase II Clinical Trial Evaluating Combination of ImmunoPulse™ IL-12 and Anti-PD-1 Treatment (August 18, 2015)
OncoSec Medical Issues Annual Letter To Shareholders (June 17, 2015)
OncoSec Medical Enrolls First Patient in Squamous Cell Carcinoma of the Head and Neck Phase II Clinical Trial (June 16, 2015)
OncoSec Medical Set to Join Russell Microcap Index (June 15, 2015)
OncoSec Medical Announces Uplisting to The NASDAQ Stock Market LLC (May 27, 2015)
OncoSec Medical and Massachusetts General Hospital to Evaluate Efficacy of Intratumoral Delivery of DNA-Based Interleukin-12 (May 18, 2015)
OncoSec Medical Announces FINRA Approval of Reverse Stock Split (May 15, 2015)
OncoSec Medical Inc. and Heat Biologics, Inc. Announce Collaboration to Evaluate Combination of Immunotherapy Platforms (February 18, 2015)
OncoSec Medical Announces New Phase II Trial in Head and Neck Cancer Using ImmunoPulse (December 9, 2014)
UC San Francisco and OncoSec Medical Collaborate to Evaluate Investigational Combination of ImmunoPulse and Anti-PD-1 Treatment (November 25, 2014)
OncoSec Medical Appoints Dr. Holbrook Kohrt to Scientific Advisory Board (August 6, 2014)
OncoSec Medical Appoints Dr. Soldano Ferrone to Scientific Advisory Board (June 25, 2014)
OncoSec Medical Names Adil Daud, M.D. as Chief Clinical Strategist (April 23, 2014)
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development (April 21, 2014)
OncoSec Medical To Relaunch Phase II Cutaneous T-Cell Lymphoma Study at Key Centers of Excellence (April 7, 2014)
OncoSec Announces Positive Interim Data From Phase II Study (December 16, 2013)
OncoSec Announces Hire of Chief Medical Officer (December 12, 2013)
OncoSec Medical Announces Positive Preliminary Safety Data in Combination Study (October 8, 2013)
OncoSec Medical Presents Positive Immune Response Data from Phase II Study at the 8th World Congress of Melanoma (July 22, 2013)
OncoSec Collaborates with Smart Patients to Form New Online Community for Patients Co-Founded by Former Chief Health Strategist of Google
(April 18, 2013)
OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients (March 25, 2013)
OncoSec Medical Announces Formation of Melanoma Advisory Board (February 26, 2013)
OncoSec Medical Announces 2013 Milestones and Corporate Strategy (January 15, 2013)
OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
(November 15, 2012)
OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients (November 14, 2012)
OncoSec Receives CE Mark for its Electroporation Device (October 17, 2012)
Click this link to view ONCS chart: http://stockcharts.com/h-sc/ui?s=ONCS&p=D&yr=0&mn=3&dy=0&id=p75914482749
1 in 5 Americans will be diagnosed with skin cancer in their lifetime.
Each Year 125,000 new cases of melanoma, 3,000 new cases of CTCL, and 1,500 new cases of Merkel-cell carcinoma are diagnosed.
25-29 In women age 25-29, melanoma is the most common form of cancer.
Fighting Cancer with the Body's Immune System
IMMUNOPULSE uses the body's immune system to target and destroy both local and metastasized cancer cells.
Using the OMS system, DNA IL-12 (a plasmid DNA construct with instructions to produce the IL-12 protein) is delivered into the electroporated cells. Upon entry, the gene triggers each cell to produce and
secrete the IL-12 protein, which in turn identifies and eliminates cancerous cells as part of a natural immune response.
Introducing pro-inflammatory cytokine proteins into the body as a potential anti-cancer therapy has produced encouraging data. For example, interleukin-12 (IL-12) cytokine is a naturally occurring protein
that activates and increases the levels of circulating macrophages and cytotoxic T-cells. In turn, this activity eliminates both foreign organisms and emerging cancerous cells.
In the past, cytokines were not considered a viable anti-cancer therapy because toxic levels were required to achieve an effective dose. However, when cytokines are delivered using DNA and the
OMS system, effective results can be achieved with a significantly reduced dosage, making this a viable treatment for both local and metastatic melanoma.
Initial evidence suggests that this gene therapy has the potential to not only treat cancer cells in the target area, but to also trigger immune responses affecting remote cancer cells outside the direct
treatment area including distant lesions.
View the following video for a brief explanation of how OncoSec's methods work:
ImmunoPulse has demonstrated both safety and efficacy in a Phase 1 clinical trial for metastatic melanoma. It is currently being advanced in a Phase 2 confirmatory study enrolling at six centers
throughout the US.
PHASE I METASTATIC MELANOMA HIGHLIGHTS:
-- 90% OF TREATED LESIONS DEMONSTRATED LOCAL CONTROL.
-- 53% OF PATIENTS WITH METASTATIC DISEASE SHOWED OBJECTIVE RESPONSE.
-- 16% OF PATIENTS SHOWED COMPLETE REGRESSION.
Targeting Cancer Cells with Greater Accuracy
NeoPulse boosts the effectiveness of an anti-cancer drug to kill cancer cells while minimizing toxic side effects.
NeoPulse uses the OMS system to destroy cancer cells using less harmful doses of bleomycin, a highly effective but also highly toxic anti-cancer drug.
Traditionally, bleomycin must be administered by intravenous infusion. Because this method targets cancer cells inefficiently, high doses must be used and significant side effects are common.
Using NeoPulse to electroporate and directly target cancerous cells with bleomycin, an effective result can be achieved with 1/20th of a traditional chemotherapy dose. In fact, by opening the cell membrane, we can enhance the
drug's ability to kill tumor cells by a factor of as much as 4,000.
Intensifying an already powerful drug
Bleomycin is proven to destroy cancer cells by attacking their DNA via an apoptotic or "suicidal" mechanism. When administered to cancer cells directly through electroporation, the efficacy of bleomycin
is increased exponentially. Even more advantageous, the pores of treated cells close shortly after introduction of the drug, trapping it within. Tests show that electroporated cells retain more of the drug, and retain it for a
longer period, thereby increasing the effectiveness of the treatment.
Extensive pre-clinical and clinical data from Phase 1 through 4 clinical trials demonstrate NeoPulse is safe and highly effective in eradicating solid tumors, including melanoma, basal cell
carcinoma, squamous cell carcinoma, and liver and pancreatic cancers, with observable cancer cell destruction, better quality of life benefits, and swift healing of the wound site.
HEAD AND NECK CANCER HIGHLIGHTS:
US PHASE III
-- 90% SUCCESS IN KILLING LOCALLY RECURRENT OR SECONDARY PRIMARY TUMOR.
-- 8 MONTHS ON AVERAGE, PATIENTS WHO RECEIVED OUR TREATMENT LIVED 8 MONTHS (EQUAL TO SURGERY).
EUROPEAN PHASE IV
-- 94% SUCCESS IN KILLING LOCAL PRIMARY TUMORS WITHOUT ANY RECURRENCE (MONITORED FOR 8 MONTHS).
OMS-I100 - Phase II Metastatic Melanoma Clinical Trial
Approximately 70,000 new cases of melanoma will be diagnosed every year, and this number is increasing. Despite this cancer being the deadliest form of all skin cancers, there still
remain few treatment options for patients with advanced-stage disease.
Previous data from a Phase I study demonstrated that using ImmunoPulse in melanoma patients is safe and well tolerated. In addition, promising therapeutic outcomes were observed
in 53% of patients with metastaticdisease, demonstrating an objective response to this therapy.
A Phase II safety and efficacy trial using OMS electroporation to deliver DNA IL-12 in patients with late-stage metastatic melanoma (OMS-I100) is being conducted in collaboration with the University of
California San Francisco. This open-label, multi-center Phase II trial will enroll approximately 25 patients with advanced-stage, cutaneous, in-transit malignant melanoma. Trials are currently being
conducted at three centers across the United States.
Further information: http://clinicaltrials.gov/ct2/show/NCT01502293?term=clinical+trials+adil+daud&rank=2
OMS-I110 - Phase II Merkel Cell Carcinoma Clinical Trial
Merkel cell carcinoma is a rare and deadly disease. Despite a mortality rate of 40%, treatment options for these patients are scarce. Because 80% of Merkel cell carcinomas are caused by an associated
viral infection (Merkel cell polyomavirus), it is believed that an efficient and targeted immunotherapy may be a potential therapeutic approach for this disease.
A Phase II safety and efficacy trial using OMS ElectroImmunotherapy to deliver DNA IL-12 in patients with local and metastatic Merkel cell carcinoma (OMS-I110) is being conducted in collaboration with the
University of Washington. This open-label, multi-center Phase II trial will enroll approximately 15 patients with Merkel cell carcinoma. Trials are currently being conducted at two centers in the United States.
Further information: http://www.clinicaltrials.gov/ct2/show/NCT01440816?term=merkel+cell+carcinoma&rank=3
OMS-I120 - Phase II Cutaneous T-Cell Lymphoma Clinical Trial
Cutaneous t-cell lymphoma is a rare form of non-Hodgkin's lymphoma that affects T-cells of the immune system, resulting in immune dysfunction. Though not life-threatening, this disease has proven
difficult to treat, with current therapies unable to demonstrate long-term benefits.
As a disease of the immune system, cutaneous T-cell lymphoma may be responsive to immunotherapy, a treatment in which the immune system is stimulated to fight cancer and destroy infected cells.
Immunotherapy has the potential to provide safe and long-lasting treatment.
A Phase II safety and efficacy trial using ImmunoPulse to deliver DNA IL-12 (a gene that triggers cells to attack and eliminate cancerous cells) in patients with early and late stage cutaneous T-cell
lymphoma (OMS-I120) is being conducted in collaboration with the University of California San Francisco. This open-label, multi-center Phase II trial will enroll approximately 27 patients with cutaneous
T-cell lymphoma. Trials are currently being conducted at one center in the United States.
Further information: http://clinicaltrials.gov/ct2/show/NCT01579318?term=CTCL+UCSF&rank=1
7 Key Questions & Answers
When and why was OncoSec formed?
OncoSec was formed in March 2011 and is led by a management team with 10 years of experience in developing electroporation technologies for the treatment of cancer. In total, more than $100 million
has been invested in the development of OncoSec's proprietary electroporation technology. Today, OncoSec is focused on refining this late-stage technology and developing a robust clinical pipeline focused on treating rare
skin cancers by delivering targeted chemotherapies and immunotherapies using electroporation.
Why is electroporation important?
Since the 1950s, a number of potentially useful drugs have been developed to treat cancer. However, the method for delivering these drugs has always been inadequate and problematic. Traditionally,
most drugs are delivered systemically: they are administered through an IV and directly into the bloodstream. When drugs are delivered this way, high concentrations of the drug are needed to reach the
cancer. At these concentrations, many of these drugs are highly toxic.
For the first time, there is a more efficient and targeted method of delivering cancer-fighting drugs.
Using a brief electrical pulse, electroporation temporarily opens the pores of cancer cells, allowing us to deliver drugs directly into those cells. This way, we can dramatically reduce the drug
concentration required to achieve therapeutic results.
What is the market size for OncoSec's target indications?
Today, more than two million skin cancers are diagnosed each year in the US alone. Most are non-deadly cancers called basal cell carcinomas and squamous cell carcinomas. These can be treated with
surgery, but surgical intervention can result in damaging cosmetic or functional outcomes.
Skin cancers can also be highly lethal and difficult-sometimes even impossible-to treat using conventional methods. These cancers including melanoma, Merkel cell carcinoma, and cutaneous T-cell
There are 125,000 new cases of melanoma diagnosed each year, and this number is increasing, especially among young adults ages 18-35. Treatments are toxic, debilitating, and not always effective.
There are also 3,000 new cases of cutaneous T-cell lymphoma and 1,500 new cases of Merkel-cell carcinoma diagnosed each year in the US. Instances of these cancers, too, are increasing, and there are
currently no treatments available for these patients.
OncoSec's electroporation technologies target these potentially lethal and hard-to-treat skin cancers that conventional therapies can't reach effectively.
OncoSec's therapies have shown significant improvements in response compared to currently approved therapies. Just as important, they have been shown to trigger significantly fewer or less-intense side effects compared
to conventional treatment, thereby improving patients' quality of life as well as their longevity.
NeoPulse is being developed to treat primary and recurrent cancers that have not yet spread to other parts of the body. For these types of cancers, surgery is a possible treatment, but one that can have detrimental
cosmetic and functional effects because of the healthy surrounding tissue that is often excised. As an alternative therapy, NeoPulse can target and kill cancer cells while keeping the surrounding healthy tissue intact. This results in a less-invasive treatment with improved outcomes. NeoPulse also has the potential to minimize the risk of recurrence compared to surgery, because the cancerous cells can be targeted and killed with greater precision.